Is ACTU or ARTV more profitable?

Artiva Biotherapeutics' return on equity of -73.15% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -430.93% -180.86% Artiva Biotherapeutics N/A -73.15% -62.74%

Does the media refer more to ACTU or ARTV?

In the previous week, Artiva Biotherapeutics had 8 more articles in the media than Actuate Therapeutics. MarketBeat recorded 11 mentions for Artiva Biotherapeutics and 3 mentions for Actuate Therapeutics. Artiva Biotherapeutics' average media sentiment score of 0.91 beat Actuate Therapeutics' score of 0.62 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Artiva Biotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, OKUR or ACTU?

Actuate Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OnKure Therapeutics N/A N/A -$59.52M -$4.33 N/A Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A

Is OKUR or ACTU more profitable?

OnKure Therapeutics' return on equity of -61.02% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets OnKure Therapeutics N/A -61.02% -55.99% Actuate Therapeutics N/A -430.93% -180.86%

Does the media favor OKUR or ACTU?

In the previous week, Actuate Therapeutics had 1 more articles in the media than OnKure Therapeutics. MarketBeat recorded 3 mentions for Actuate Therapeutics and 2 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 0.94 beat Actuate Therapeutics' score of 0.62 indicating that OnKure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OnKure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Actuate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ACTU or IPHA?

Actuate Therapeutics has higher earnings, but lower revenue than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A Innate Pharma $10.19M 16.22 -$55.64M N/A N/A

Is ACTU or IPHA more profitable?

Innate Pharma's return on equity of 0.00% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -430.93% -180.86% Innate Pharma N/A N/A N/A

Which has stronger earnings and valuation, ACTU or ABOS?

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A Acumen Pharmaceuticals N/A N/A -$121.33M -$1.86 N/A

Is ACTU or ABOS more profitable?

Acumen Pharmaceuticals' return on equity of -123.07% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -430.93% -180.86% Acumen Pharmaceuticals N/A -123.07% -79.41%

Does the media prefer ACTU or ABOS?

In the previous week, Acumen Pharmaceuticals had 1 more articles in the media than Actuate Therapeutics. MarketBeat recorded 4 mentions for Acumen Pharmaceuticals and 3 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.62 beat Acumen Pharmaceuticals' score of 0.59 indicating that Actuate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acumen Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ACTU or CNTN?

Actuate Therapeutics currently has a consensus target price of $17.50, indicating a potential upside of 766.34%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Actuate Therapeutics is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, ACTU or CNTN?

Hillstream Biopharma is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A Hillstream Biopharma N/A N/A -$35.92M -$1.15 N/A

Is ACTU or CNTN more profitable?

Hillstream Biopharma's return on equity of -31.50% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -430.93% -180.86% Hillstream Biopharma N/A -31.50% -24.72%

Actuate Therapeutics (ACTU) Competitors

$2.02 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$1.98 -0.03 (-1.73%)

As of 06/12/2026 07:56 PM Eastern

Compare

ACTU vs. ARTV, OKUR, IPHA, ABOS, and CNTN

Should you buy Actuate Therapeutics stock or one of its competitors? MarketBeat compares Actuate Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Actuate Therapeutics include Artiva Biotherapeutics (ARTV), OnKure Therapeutics (OKUR), Innate Pharma (IPHA), Acumen Pharmaceuticals (ABOS), and Hillstream Biopharma (CNTN). These companies are all part of the "pharmaceutical products" industry.

How does Actuate Therapeutics compare to Artiva Biotherapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Actuate Therapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.4, indicating that its stock price is 140% more volatile than the broader market.

In the previous week, Artiva Biotherapeutics had 8 more articles in the media than Actuate Therapeutics. MarketBeat recorded 11 mentions for Artiva Biotherapeutics and 3 mentions for Actuate Therapeutics. Artiva Biotherapeutics' average media sentiment score of 0.91 beat Actuate Therapeutics' score of 0.62 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actuate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Artiva Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Artiva Biotherapeutics' return on equity of -73.15% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
Artiva Biotherapeutics	N/A	-73.15%	-62.74%

Actuate Therapeutics has higher earnings, but lower revenue than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
Artiva Biotherapeutics	$250K	844.44	-$83.86M	-$3.54	N/A

Actuate Therapeutics presently has a consensus target price of $17.50, indicating a potential upside of 766.34%. Artiva Biotherapeutics has a consensus target price of $39.00, indicating a potential upside of 356.67%. Given Actuate Therapeutics' higher probable upside, equities research analysts plainly believe Actuate Therapeutics is more favorable than Artiva Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Artiva Biotherapeutics beats Actuate Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Actuate Therapeutics compare to OnKure Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

OnKure Therapeutics has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

91.0% of OnKure Therapeutics shares are owned by institutional investors. 17.9% of OnKure Therapeutics shares are owned by company insiders. Comparatively, 58.0% of Actuate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

OnKure Therapeutics currently has a consensus target price of $27.00, suggesting a potential upside of 542.86%. Actuate Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 766.34%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than OnKure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Actuate Therapeutics had 1 more articles in the media than OnKure Therapeutics. MarketBeat recorded 3 mentions for Actuate Therapeutics and 2 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 0.94 beat Actuate Therapeutics' score of 0.62 indicating that OnKure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Actuate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OnKure Therapeutics' return on equity of -61.02% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-61.02%	-55.99%
Actuate Therapeutics	N/A	-430.93%	-180.86%

Actuate Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A

Summary

Actuate Therapeutics beats OnKure Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Actuate Therapeutics compare to Innate Pharma?

Actuate Therapeutics (NASDAQ:ACTU) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Actuate Therapeutics has higher earnings, but lower revenue than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
Innate Pharma	$10.19M	16.22	-$55.64M	N/A	N/A

Actuate Therapeutics currently has a consensus price target of $17.50, suggesting a potential upside of 766.34%. Innate Pharma has a consensus price target of $5.00, suggesting a potential upside of 184.09%. Given Actuate Therapeutics' higher probable upside, research analysts plainly believe Actuate Therapeutics is more favorable than Innate Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

0.2% of Innate Pharma shares are held by institutional investors. 58.0% of Actuate Therapeutics shares are held by insiders. Comparatively, 31.9% of Innate Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Actuate Therapeutics had 2 more articles in the media than Innate Pharma. MarketBeat recorded 3 mentions for Actuate Therapeutics and 1 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 1.89 beat Actuate Therapeutics' score of 0.62 indicating that Innate Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Actuate Therapeutics	Positive
Innate Pharma	Very Positive

Innate Pharma's return on equity of 0.00% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
Innate Pharma	N/A	N/A	N/A

Actuate Therapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

Summary

Innate Pharma beats Actuate Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Actuate Therapeutics compare to Acumen Pharmaceuticals?

Actuate Therapeutics (NASDAQ:ACTU) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

Actuate Therapeutics currently has a consensus target price of $17.50, indicating a potential upside of 766.34%. Acumen Pharmaceuticals has a consensus target price of $6.67, indicating a potential upside of 181.29%. Given Actuate Therapeutics' higher probable upside, equities research analysts plainly believe Actuate Therapeutics is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 58.0% of Actuate Therapeutics shares are owned by company insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A

Actuate Therapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market.

In the previous week, Acumen Pharmaceuticals had 1 more articles in the media than Actuate Therapeutics. MarketBeat recorded 4 mentions for Acumen Pharmaceuticals and 3 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.62 beat Acumen Pharmaceuticals' score of 0.59 indicating that Actuate Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actuate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Acumen Pharmaceuticals' return on equity of -123.07% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

Summary

Acumen Pharmaceuticals beats Actuate Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Actuate Therapeutics compare to Hillstream Biopharma?

Actuate Therapeutics (NASDAQ:ACTU) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Actuate Therapeutics currently has a consensus target price of $17.50, indicating a potential upside of 766.34%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Actuate Therapeutics is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Actuate Therapeutics had 2 more articles in the media than Hillstream Biopharma. MarketBeat recorded 3 mentions for Actuate Therapeutics and 1 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 1.89 beat Actuate Therapeutics' score of 0.62 indicating that Hillstream Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Actuate Therapeutics	Positive
Hillstream Biopharma	Very Positive

Actuate Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

1.2% of Hillstream Biopharma shares are owned by institutional investors. 58.0% of Actuate Therapeutics shares are owned by company insiders. Comparatively, 6.7% of Hillstream Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Hillstream Biopharma's return on equity of -31.50% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
Hillstream Biopharma	N/A	-31.50%	-24.72%

Hillstream Biopharma is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A

Summary

Actuate Therapeutics beats Hillstream Biopharma on 8 of the 13 factors compared between the two stocks.

Get Actuate Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACTU vs. The Competition

Export

Metric	Actuate Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$48.34M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-2.08	20.00	24.00	24.42
Price / Sales	N/A	303.75	533.77	123.88
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	5.94	8.32	10.55	6.82
Net Income	-$22.23M	$23.94M	$3.57B	$337.56M
7 Day Performance	10.99%	1.84%	0.59%	1.16%
1 Month Performance	-22.90%	-0.04%	1.55%	3.16%
1 Year Performance	-76.65%	44.82%	25.41%	30.60%

Actuate Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACTU Actuate Therapeutics	2.0528 of 5 stars	$2.02 flat	$17.50 +766.3%	-76.6%	$48.34M	N/A	N/A	10	High Trading Volume
ARTV Artiva Biotherapeutics	3.869 of 5 stars	$7.05 +2.6%	$39.00 +453.2%	+331.3%	$174.28M	$250K	N/A	81	News Coverage Short Interest Increase
OKUR OnKure Therapeutics	2.7652 of 5 stars	$4.31 +2.1%	$27.00 +526.5%	+58.5%	$174.12M	N/A	N/A	N/A
IPHA Innate Pharma	3.2999 of 5 stars	$1.81 -0.5%	$5.00 +176.2%	-7.1%	$170.00M	$10.19M	N/A	220
ABOS Acumen Pharmaceuticals	2.5217 of 5 stars	$2.33 -1.7%	$6.67 +186.1%	+121.5%	$168.29M	N/A	N/A	20	Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACTU) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Actuate Therapeutics (ACTU) Competitors

ACTU vs. ARTV, OKUR, IPHA, ABOS, and CNTN

How does Actuate Therapeutics compare to Artiva Biotherapeutics?

Summary

How does Actuate Therapeutics compare to OnKure Therapeutics?

Summary

How does Actuate Therapeutics compare to Innate Pharma?

Summary

How does Actuate Therapeutics compare to Acumen Pharmaceuticals?

Summary

How does Actuate Therapeutics compare to Hillstream Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACTU vs. The Competition

Actuate Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Actuate Therapeutics (ACTU) Competitors

ACTU vs. ARTV, OKUR, IPHA, ABOS, and CNTN

How does Actuate Therapeutics compare to Artiva Biotherapeutics?

Which has more risk & volatility, ACTU or ARTV?

Does the media refer more to ACTU or ARTV?

Is ACTU or ARTV more profitable?

Which has preferable valuation and earnings, ACTU or ARTV?

Do analysts recommend ACTU or ARTV?

Summary

How does Actuate Therapeutics compare to OnKure Therapeutics?

Which has more volatility & risk, OKUR or ACTU?

Do insiders and institutionals hold more shares of OKUR or ACTU?

Do analysts recommend OKUR or ACTU?

Does the media favor OKUR or ACTU?

Is OKUR or ACTU more profitable?

Which has better valuation and earnings, OKUR or ACTU?

Summary

How does Actuate Therapeutics compare to Innate Pharma?

Which has better earnings and valuation, ACTU or IPHA?

Do analysts rate ACTU or IPHA?

Do insiders & institutionals have more ownership in ACTU or IPHA?

Does the media favor ACTU or IPHA?

Is ACTU or IPHA more profitable?

Which has more risk & volatility, ACTU or IPHA?

Summary

How does Actuate Therapeutics compare to Acumen Pharmaceuticals?

Do analysts rate ACTU or ABOS?

Do insiders and institutionals have more ownership in ACTU or ABOS?

Which has stronger earnings and valuation, ACTU or ABOS?

Which has more risk and volatility, ACTU or ABOS?

Does the media prefer ACTU or ABOS?

Is ACTU or ABOS more profitable?

Summary

How does Actuate Therapeutics compare to Hillstream Biopharma?

Do analysts rate ACTU or CNTN?

Does the media prefer ACTU or CNTN?

Which has more volatility & risk, ACTU or CNTN?

Do institutionals and insiders have more ownership in ACTU or CNTN?

Is ACTU or CNTN more profitable?

Which has preferable earnings & valuation, ACTU or CNTN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACTU vs. The Competition

Actuate Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools